Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Potentia Pharmaceuticals Licenses Complement Inhibitor Compstatin from the University of Pennsylvania
July 27, 2006
Louisville, Ky. – Potentia Pharmaceuticals, Inc. announced today that it has entered into an exclusive, worldwide licensing agreement with the University of Pennsylvania that provides broad rights to develop and commercialize University of Pennsylvania's Compstatin class of complement-inhibiting peptides for the treatment of ocular diseases. While the terms of the license have not been disclosed, this agreement will allow Potentia to move forward with the preclinical development of the first complement-inhibiting drug product aimed at treating both the "wet" and "dry" forms of age-related macular degeneration (ARMD).
"We are excited to work with the University of Pennsylvania in developing the first treatment for macular degeneration based on the important genetic findings of the last year" said Cedric Francois, M.D., Ph.D., Chief Executive Officer for Potentia. "Genetic analysis of patients with macular degeneration has now clearly established that excessive complement activation is involved in the development of macular degeneration. Compstatin is one of the best complement-inhibiting drugs available and we look forward to evaluate its potential and to help patients suffering from this devastating disease."